ODT
NASDAQOdonate Therapeutics Inc.
Odonate Therapeutics Inc. (ODT) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for ODT in the last 30 days. The most recent was published Jan 25, 2022.
Latest news
25 items- SECSEC Form 25-NSE filed by Odonate Therapeutics Inc.25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)
- NEWS60 Biggest Movers From YesterdayGainers Bone Biologics Corporation (NASDAQ:BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ:ZNGA) rose 40.7% to settle at $8.44 after the company announced it will be acquired by Take-Two Interactive Software in a cash and stock transaction valued at $9.86 per Zynga share, representing a total enterprise value of approximately $12.7 billion. Molecular Partners AG (NASDAQ:MOLN) surged 30.5% to settle at $21.50 after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19. Reliance Global Group, Inc. (NASDAQ:RELI) climbed 28.9% to close at $7.86. Reliance Global Group, last month, announc
- NEWS56 Biggest Movers From FridayGainers Hour Loop, Inc. (NASDAQ:HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ:HGSH) shares surged 57.5% to close at $3.48 on Friday. Traders may be viewing this stock as a play on a Friday deal by Papa John's to expand its presence in China by 1,350 stores. The Papa John's press release did not specifically mention a real estate company it would be working with for the expansion. ATA Creativity Global (NASDAQ:AACG) gained 33.3% to settle at $2.64. Marin Software Incorporated (NASDAQ:MRIN) shares jumped 31.3% to close at $4.53 on Friday after the company announced an integration with Amazon Ads' demand-side platfo
- NEWSOdonate Therapeutics shares are trading lower after the company received notice from The Nasdaq Stock Market that the continued listing of its securities is no longer warranted.
- NEWS12 Health Care Stocks Moving In Friday's Intraday SessionGainers Absci (NASDAQ:ABSI) stock increased by 28.2% to $7.87 during Friday's regular session. As of 12:30 EST, Absci's stock is trading at a volume of 38.6 million, which is 15366.1% of its average full-day volume over the last 100 days. The company's market cap stands at $728.6 million. Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 15.8% to $2.02. Trading volume for Quoin Pharmaceuticals's stock is 41.2 million as of 12:30 EST. This is 3934.9% of its average full-day volume over the last 100 days. The company's market cap stands at $16.8 million. Anixa Biosciences (NASDAQ:ANIX) shares increased by 15.06% to $3.36. Trading volume for this security as of 12:30 EST is 213
- NEWSStocks That Hit 52-Week Lows On FridayBefore 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap basis to set a new 52-week low. Reshape Lifesciences (NASDAQ:RSLS) was the smallest firm on a market cap basis to set a new 52-week low. Aligos Therapeutics (NASDAQ:ALGS)'s stock moved significantly downwards, trading down 46.75% to reach a new 52-week low. Athenex (NASDAQ:ATNX) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. Stocks that set new 52-week lows during the first half-hour of trading on Friday are as follows: Humana (NYSE:HUM) stock hi
- NEWSOdonate Therapeutics Announces Expected Delisting Of StockOdonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The N
- SECOdonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
- PROdonate Announces Expected Delisting of Its StockOdonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The
- NEWSStocks That Hit 52-Week Lows On ThursdayOn Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows And Highs: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company by market cap to hit a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). Aligos Therapeutics (NASDAQ:ALGS) saw the largest move of the companies, as shares plummetted 46.75% to hit a new 52-week low. Vimeo (NASDAQ:VMEO) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The following stocks created new 52-week lows as of 10am on Thursday: Rivian Automotive (NASDAQ:RIVN) stock achieved a new 52-week low on Thursday morning, hitting $75
- INSIDERSEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
- 13D/GSEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
- NEWS12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers Aptinyx (NASDAQ:APTX) shares rose 4.72% to $2.66 during Wednesday's after-market session. Trading volume for this security closed at 80.2K, accounting for 49.36% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $180.1 million. iSpecimen (NASDAQ:ISPC) shares rose 4.24% to $14.75. The market value of their outstanding shares is at $128.5 million. Reshape Lifesciences (NASDAQ:RSLS) stock rose 3.96% to $2.1. The company's market cap stands at $7.3 million. Bluejay Diagnostics (NASDAQ:BJDX) stock rose 3.86% to $2.69. The market value of their outstanding shares is at $34.1 million. Odonate Therapeutics (NASDAQ:ODT) stock rose 3
- 13D/GSEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
- INSIDERSEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
- INSIDERSEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
- INSIDERSEC Form 4: Boxer Capital, Llc sold $2,062,775 worth of shares (1,000,000 units at $2.06)4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
- INSIDERSEC Form 4: Tang Kevin C sold $5,730,557 worth of shares (2,747,131 units at $2.09)4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
- SECOdonate Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
- 13D/GSEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
- INSIDERSEC Form 3: New insider Ecor1 Capital, Llc claimed ownership of 5,701,669 shares3 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
- PROdonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase PlanOdonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou
- PROdonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In
ODT FAQ
7 questionsWhat does Odonate Therapeutics Inc. do?
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.What is the latest news on ODT?
Quantisnow has not tracked any new filings, ratings or press releases for ODT in the last 30 days. The most recent wire item was published on January 25, 2022.Where does ODT stock trade?
Odonate Therapeutics Inc. (ODT) is listed on NASDAQ.What sector and industry is ODT in?
Odonate Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Odonate Therapeutics Inc. go public?
Odonate Therapeutics Inc. (ODT) completed its IPO in 2017.What companies are similar to ODT?
Notable peers in the same industry include MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare ODT side-by-side with any of them on Quantisnow.How can I track ODT on Quantisnow?
Quantisnow aggregates Odonate Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ODT to receive live email and push alerts on every new disclosure.